A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Ipsen
University of Nebraska
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Roswell Park Cancer Institute
Royal Marsden NHS Foundation Trust
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Stanford University
Masonic Cancer Center, University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
AIDS Malignancy Consortium
SWOG Cancer Research Network
Children's Oncology Group
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Northwestern University
Northwestern University
Swiss Cancer Institute
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)